Medical Cannabis for Mental Health |
A molecule in cannabis (CBD) has shown to relieve anxiety and symptoms of psychosis in people diagnosed with schizophrenia, though many patients are denied or discouraged from this medicine with fewer side effects than pharmaceutical products because the DEA has deemed the cannabis plant to be “illegal”. The U.S. government needs to answer “why?” this medicine warrents time in prison when nobody is being harmed.
Study: Administration Of Non-Psychotropic Cannabinoid Mitigates Psychotic Symptoms In Schizophrenics
The administration of the non-psychotropic plant constituent cannabidiol (CBD) is associated with a significant reduction in psychotic symptoms in patients with schizophrenia, according to clinical trial data published in the journal Translational Psychiatry.
An international team of researchers from Germany and the United States performed a four week, double-blind, randomized clinical trial assessing the clinical relevance of cannabidiol versus amisulpride, a potent antipsychotic agent, in patients with acute schizophrenia.
Researchers reported that the administration of either substance was associated with significant clinical improvement, but they acknowledged, “[C]annabidiol displayed a markedly superior side-effect profile.”
Amisulpride is categorized as “one of the most effective drugs currently in use for the treatment of schizophrenia.”
Investigators concluded, “Our results provide evidence that the non-cannabimimetic constituent of marijuana, cannabidiol, exerts clinically relevant antipsychotic effects that are associated with marked tolerability and safety, when compared with current medications. … The results … potentially represent a completely new mechanism in the treatment of schizophrenia.”
A review of CBD’s safety profile in humans, published online in 2011 in the scientific journal Current Drug Safety, concluded that the cannabinoid is non-toxic, safe, and well tolerated in humans, even in high doses.
Separate investigations of CBD have documented the cannabinoid to possess a variety of therapeutic properties, including anti-inflammatory, anti-diabetic, anti-epileptic, anti-cancer, and bone-stimulating properties.
For more information, please contact Paul Armentano, NORML Deputy Director, at: paul [at] norml.org. Full text of the study, “Cannabidiol enhances anandamide signaling and alleviates psychotic symptoms of schizophrenia,” is available online here:http://www.nature.com/tp/journal/v2/n3/full/tp201215a.html.
Article From NORML and republished with permission
Is There Anything CBD Can’t Do? Then Why Is It Illegal?
-by Paul Armentano, NORML Deputy DirectorOctober 9, 2008
While the prohibition of cannabis is absurd, the ban on the plant’s non-psychoactive components is even more mind-boggling – particularly when it’s apparent that these compounds possess amazing therapeutic properties. Case in point: cannabidiol (CBD).
A just published scientific review by Sao Paulo University (Brazil) researcher Antonio Zuardi reports that there’s been an “explosive increase” of interest in CBD over the past five years. It’s apparent why.
“Studies have suggested a wide range of possible therapeutic effects of cannabidiol on several conditions, including Parkinson’s disease, Alzheimer’s disease, cerebral ischemia, diabetes, rheumatoid arthritis, other inflammatory diseases, nausea and cancer,” Zuardi writes. Let’s look at a few of these in detail, shall we?
1. Antiepileptic action
“In 1973, a Brazilian group reported that CBD was active in … blocking convulsions produced in experimental animals.”
2. Sedative action
“In humans with insomnia, high doses of CBD increased sleep duration compared to placebo.”
3. Anxiolytic action
“CBD induce[s] a clear anxiolytic effect and a pattern of cerebral activity compatible with an anxiolytic activity.”
4. Antipsychcotic action
“[C]linical studies suggest that CBD is an effective, safe and well-tolerated alternative treatment for schizophrenic patients.”
5. Antidystonic action
“CBD … had antidystonic effects in humans when administered along with standard medication to five patients with dystonia, in an open study.”
6. Antioxidative action
“[I]t was demonstrated that CBD can reduce hydroperoxide-induced oxidative damage as well as or better than other antioxidants. CBD was more protective against glutamate neurotoxicity than either ascorbate or a-tocopherol, indicating that this drug is a potent antioxidant.”
7. Neuroprotective action
“A marked reduction in the cell survival was observed following exposure of cultured rat pheochromocytoma PC12 cells to beta-A peptide. Treatment of the cells with CBD prior to beta-A exposure significantly elevated the cell survival.”
8. Antiinflammatory action
“CBD, administered i.p. or orally, has blocked the progression of arthritis.”
9. Cardioprotective action
“CBD induces a substantial cardioprotective effect.”
10. Action on diabetes
“CBD treatment of NOD (non-obese diabetic) mice before the development of the disease reduced its incidence from 86% in the non-treated control mice to 30% in CBD-treated mice. … It was also observed that administration of CBD to 11-14 week old female NOD mice, which were either in a latent diabetes stage or had initial symptoms of diabetes, ameliorated the manifestations of the disease.”
11. Antiemetic action
“The expression of this conditioned retching reaction was completely suppressed by CBD and delta9-THC, but not by ondansetron, [an] antagonist that interferes with acute vomiting.”
12. Anticancer action
“A study of the effect of different cannabinoids on eight tumor cell lines, in vitro, has clearly indicated that, of the five natural compounds tested, CBD was the most potent inhibitor of cancer cell growth.”
In sum, the past 45 years of scientific study on CBD has revealed the compound to be non-toxic, non-psychoactive, and to possess a multitude of therapeutic properties. Yet, to this day it remains illegal to possess or use (and nearly impossible to study in US clinical trials) simply because it is associated with marijuana.
What possible advancements in medical treatment may have been achieved over the past decades had US government officials chosen to advance – rather than inhibit – clinical research into CBD (which, under federal law, remains a Schedule I drug defined as having “no currently accepted medical use”)? Perhaps it’s time someone asks John Walters or the DEA?
additional info on CBD;
BTW – Not all people with schizophrenia who use cannabis will be symptom free, though many are considerably less violent than if they had no medicine, or like zombies (see “Thorazine shuffle”) on the pharmacuetical products.
Paranoia from the THC molecule in cannabis is no doubt aggravated by the U.S. government policy of cannabis prohibition. Schizophrenics using medical cannabis and cops or feds looking for a quick bust in the non-medical states are not a good combination!!
How’s that class action lawsuit against the DEA going??